U.S. Markets closed

Analysts’ Estimates and Ratings for Novartis in October

Mike Benson
Analysts’ Estimates and Ratings for Novartis in October

Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.